Metoclopramide Injection, Solution
NDC Package 36000-366-25

11-digit billing NDC: 36000036625
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Metoclopramide injection is diabetic Gastroparesis Metoclopramide injection is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults.The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer ChemotherapyMetoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults.The Prevention of Postoperative Nausea and VomitingMetoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults.Small Bowel IntubationMetoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers.Radiological ExaminationMetoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults. This formulation utilizes a injection, solution delivery system. Marketed by Baxter Healthcare Corporation, this product is identified by NDC 36000-366 and is authorized under FDA application ANDA217072.

Identification & Billing

NDC Package Code
36000-366-25
Package Description
25 VIAL, SINGLE-DOSE in 1 CARTON / 2 mL in 1 VIAL, SINGLE-DOSE (36000-366-01)
Product Code
36000-366
11-Digit Billing Format
36000036625

Clinical Specifications

Proprietary Name
Metoclopramide
Non-Proprietary Name
Metoclopramide
Substance Name
Metoclopramide Hydrochloride
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
  • Intramuscular - Administration within a muscle.
  • Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
METOCLOPRAMIDE HYDROCHLORIDE 5 mg/mL
Pharmacologic Class
Usage Information
Diabetic Gastroparesis Metoclopramide injection is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis is in adults.The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer ChemotherapyMetoclopramide injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy in adults.The Prevention of Postoperative Nausea and VomitingMetoclopramide injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable in adults.Small Bowel IntubationMetoclopramide injection is indicated to facilitate small bowel intubation in adult and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers.Radiological ExaminationMetoclopramide injection is indicated to stimulate gastric emptying and intestinal transit of barium where delayed emptying interferes with radiological examination of the stomach and/or small intestine in adults.

Regulatory & Marketing

Labeler Name
Baxter Healthcare Corporation
Product Type
Human Prescription Drug
FDA Application #
ANDA217072
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-11-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 36000-366-25 identifies a specific commercial package of 25 vial, single-dose in 1 carton / 2 ml in 1 vial, single-dose (36000-366-01) of Metoclopramide, a human prescription drug labeled by Baxter Healthcare Corporation. This injection, solution is formulated for intramuscular; intravenous use and contains metoclopramide hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Baxter Healthcare Corporation on September 11, 2026. The current certification is valid through December 31, 2027.

How is this Baxter Healthcare Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 36000036625. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
36000-366-25
11-Digit CMS (5-4-2)
36000-0366-25

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.